Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Diphenylacetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC known ✓ | P12931 | 2/20 | 0.59 |
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.56 |
| ▸ | HDAC4 known ✓ | P56524 | 1/20 | 0.56 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC7 known ✓ | Q8WUI4 | 1/20 | 0.56 |
| ▸ | HDAC2 known ✓ | Q92769 | 1/20 | 0.56 |
| ▸ | HDAC10 known ✓ | Q969S8 | 1/20 | 0.56 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 1/20 | 0.56 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 1/20 | 0.56 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.56 |
| ▸ | HDAC9 known ✓ | Q9UKV0 | 1/20 | 0.56 |
| ▸ | HDAC5 known ✓ | Q9UQL6 | 1/20 | 0.56 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.47 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.47 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.47 |
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.45 |
| ▸ | HSD11B1 known ✓ | P28845 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diphenylacetic Acid SCHEMBL38022 | 0.97 | SRC (0.62) | SRCCYP2D6TDP1L3MBTL1LMNA | |
| Diphenylacetic Acid SCHEMBL8513250 | 0.97 | SRC (0.62) | SRCCYP2D6TDP1L3MBTL1LMNA | |
| Diphenylacetic Acid SCHEMBL28446280 | 0.94 | SRC (0.59) | SRCCYP2D6TDP1L3MBTL1LMNA | |
| Diphenylacetic Acid SCHEMBL30803718 | 0.94 | SRC (0.59) | SRCCYP2D6TDP1L3MBTL1LMNA | |
| Diphenylacetic Acid SCHEMBL27858509 | 0.94 | SRC (0.59) | SRCCYP2D6TDP1L3MBTL1LMNA | |
| Diphenylacetic Acid SCHEMBL8411440 | 0.94 | SRC (0.59) | SRCCYP2D6TDP1L3MBTL1LMNA | |
| Diphenylacetic Acid SCHEMBL6852183 | 0.94 | SRC (0.59) | SRCCYP2D6TDP1L3MBTL1LMNA | |
| Diphenylacetic Acid SCHEMBL9750917 | 0.94 | SRC (0.59) | SRCCYP2D6TDP1L3MBTL1LMNA | |
| Diphenylacetic Acid SCHEMBL9485695 | 0.94 | SRC (0.59) | SRCCYP2D6TDP1L3MBTL1LMNA | |
| Diphenylacetic Acid SCHEMBL27841008 | 0.94 | SRC (0.59) | SRCCYP2D6TDP1L3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035954-A1 | ACID ADDITION SALTS OF MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES INC. (IN) | 2010-02-11 | — | — | US | claimed |
| EP-1828126-A1 | ACID ADDITION SALTS OF MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2007-09-05 | — | — | EP | claimed |
| WO-2006064304-A1 | ACID ADDITION SALTS OF MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-06-22 | — | — | WO | claimed |
| EP-3019477-B1 | HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2021-05-26 | — | — | EP | disclosed |
| CN-107051000-A | A kind of water proof material and its manufacture method and application | 徐州工程学院 | 2017-08-18 | — | — | CN | disclosed |
| CN-107051000-A | A kind of water proof material and its manufacture method and application | 徐州工程学院 | 2017-08-18 | — | — | CN | disclosed |
| US-9714224-B2 | Heterocyclic compounds and methods of their use | NOVARTIS AG (CH) | 2017-07-25 | — | — | US | disclosed |
| EP-3081557-A1 | SALT AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | Novartis AG (CH) | 2016-10-19 | — | — | EP | disclosed |
| CN-105777636-A | SALT AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | 诺华股份有限公司 | 2016-07-20 | — | — | CN | disclosed |
| US-20160145213-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR USE | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2016-05-26 | — | — | US | disclosed |
| CN-103003244-B | Salts and solvates of tetrahydroisoquinoline derivatives | NOVARTIS AG (CH) | 2016-04-20 | — | — | CN | disclosed |
| EP-0923570-A1 | PYRIDYL ALKENE- AND PYRIDYL ALKINE- ACID AMIDES AS CYTOSTATICS AND IMMUNOSUPPRESSIVES | Klinge Pharma GmbH (DE) | 1999-06-23 | — | — | EP | disclosed |
| WO-1997048696-A1 | PYRIDYL ALKENE- AND PYRIDYL ALKINE- ACID AMIDES AS CYTOSTATICS AND IMMUNOSUPPRESSIVES | KLINGE PHARMA GMBH (DE) | 1997-12-24 | — | — | WO | disclosed |
| US-4225617-A | PSYCHOTROPIC AGENTS | LABORATOIRE L. LAFON (FR) | 1980-09-30 | — | — | US | disclosed |
| US-4209524-A | CENTRAL NERVOUS SYSTEM | LABORATOIRE L. LAFON (FR) | 1980-06-24 | — | — | US | disclosed |
| US-4209523-A | TREATMENT OF THE CENTRAL NERVOUS SYSTEM | LABORATOIRE L. LAFON (FR) | 1980-06-24 | — | — | US | disclosed |
| US-4183951-A | PSYCHOTROPIC AGENTS | LABORATOIRE L. LAFON (FR) | 1980-01-15 | — | — | US | disclosed |
| US-4152458-A | CENTRAL NERVOUS SYSTEM, PSYCHOTROPIC AGENTS | LABORATOIRE L. LAFON (FR) | 1979-05-01 | — | — | US | disclosed |
| US-4151300-A | CENTRAL NERVOUS SYSTEM, PSYCHOTROPIC | LABORATOIRE L. LAFON (FR) | 1979-04-24 | — | — | US | disclosed |
| US-4122186-A | PSYCHOTROPIC AGENTS | LABORATOIRE L. LAFON (FR) | 1978-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035954-A1 | ACID ADDITION SALTS OF MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM2 | SRC 2539/4885HDAC3 3076/4885HDAC4 2708/4885 |
| US-20160145213-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR USE | AGTR2, AGTR1, AGT | SRC 873/4885HDAC3 984/4885HDAC4 2572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.